PPARα Inhibitors
Common PPARα Inhibitors include, but are not limited to GW6471 CAS 880635-03-0, T0070907 CAS 313516-66-4, GSK 0660 CAS 1014691-61-2, BADGE CAS 1675-54-3 and Sulfasalazine CAS 599-79-1.
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. These receptors play essential roles in the regulation of cellular differentiation, development, metabolism, and tumorigenesis of higher organisms. Among the PPAR subtypes, PPARα is particularly notable for its influence on lipid metabolism in the liver. When activated, PPARα modulates the transcription of a variety of genes involved in fatty acid oxidation, lipoprotein metabolism, and other metabolic pathways. The activation of PPARα is typically mediated by ligand binding, which induces a conformational change in the receptor, allowing it to form heterodimers with retinoid X receptors (RXRs) and bind to specific DNA sequences known as PPAR response elements (PPREs).
PPARα inhibitors are a class of compounds specifically designed to antagonize the activity of PPARα. These inhibitors work by binding to the ligand-binding domain of the receptor, preventing the conformational changes required for its activation and subsequent gene transcription. By doing so, they effectively reduce or eliminate the transcriptional activity of PPARα.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW6471 | 880635-03-0 | sc-300779 | 5 mg | $289.00 | 9 | |
GW6471 is a specific antagonist of PPARα and can down-regulate its expression by directly binding and inhibiting its activity. | ||||||
T0070907 | 313516-66-4 | sc-203287 | 5 mg | $138.00 | 1 | |
T0070907 acts as an antagonist for PPARα, leading to reduced activity and potential down-regulation of the protein's expression. | ||||||
GSK 0660 | 1014691-61-2 | sc-203985 sc-203985A | 10 mg 50 mg | $172.00 $695.00 | 14 | |
GSK0660 is a selective PPARα antagonist. By binding to PPARα, it may reduce its activity and subsequent expression. | ||||||
MK-886 sodium salt | 118427-55-7 | sc-200608B sc-200608 sc-200608A | 1 mg 5 mg 25 mg | $46.00 $93.00 $371.00 | 3 | |
MK886 inhibits PPARα activation, potentially reducing its expression by blocking the ligand binding. | ||||||
BADGE | 1675-54-3 | sc-202487 sc-202487A sc-202487B sc-202487C | 25 g 50 g 100 g 500 g | $38.00 $50.00 $63.00 $189.00 | 3 | |
Bisphenol A diglycidyl ether (BADGE) acts as a PPARγ antagonist and may indirectly reduce PPARα expression through cross-talk between PPAR isoforms. | ||||||
Sulfasalazine | 599-79-1 | sc-204312 sc-204312A sc-204312B sc-204312C | 1 g 2.5 g 5 g 10 g | $60.00 $75.00 $125.00 $205.00 | 8 | |
Sulfasalazine can potentially reduce PPARα expression by inhibiting NF-kB, which may have a cross-talk with PPARα signaling. | ||||||
Oxaprozin | 21256-18-8 | sc-215641 sc-215641B sc-215641A sc-215641C sc-215641D sc-215641E | 5 mg 10 mg 50 mg 100 mg 1 g 2.5 g | $92.00 $177.00 $214.00 $275.00 $296.00 $388.00 | ||
Oxaprozin, a nonsteroidal anti-inflammatory drug, may decrease PPARα expression by affecting related metabolic pathways. | ||||||
Sodium Salicylate | 54-21-7 | sc-3520 sc-3520A sc-3520B sc-3520C | 1 g 25 g 500 g 1 kg | $10.00 $25.00 $80.00 $136.00 | 8 | |
Salicylate may down-regulate PPARα expression by inhibiting its activation and related metabolic pathways. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide, an antihelminthic drug, can down-regulate PPARα expression potentially by affecting cellular energy balance and related pathways. | ||||||
Progesterone | 57-83-0 | sc-296138A sc-296138 sc-296138B | 1 g 5 g 50 g | $20.00 $51.00 $292.00 | 3 | |
Progesterone has been reported to reduce PPARα activity, potentially leading to decreased protein expression. | ||||||